Holen Sie sich die Stockscreener-App
9.90
2.06%
0.20
Vorhandelsmarkt:
9.76
-0.14
-1.41%
Schlusskurs vom Vortag:
$9.70
Offen:
$9.73
24-Stunden-Volumen:
1.02M
Relative Volume:
0.61
Marktkapitalisierung:
$983.10M
Einnahmen:
$98.99M
Nettoeinkommen (Verlust:
$-197.98M
KGV:
-4.9458
EPS:
-2.0017
Netto-Cashflow:
$-175.32M
1W Leistung:
+6.91%
1M Leistung:
+33.33%
6M Leistung:
-1.69%
1J Leistung:
-33.20%
1-Tages-Spanne:
$9.711
$10.15
1-Wochen-Bereich:
$9.13
$10.17
52-Wochen-Spanne:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
9.90 | 974.17M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Northland Capital | Outperform |
| 2025-11-04 | Fortgesetzt | Roth Capital | Buy |
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Insider Sell: Eric Karas Sells 25,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock - Investing.com UK
Ars Pharmaceuticals CLO Alexander Fitzpatrick sells $33,550 in stock By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock - Investing.com
ARS Pharmaceuticals CCO Eric Karas sells $250,000 in stock By Investing.com - Investing.com India
ARS Pharmaceuticals (SPRY) legal chief sells 3,355 shares in planned trade - Stock Titan
[144] ARS Pharmaceuticals, Inc. SEC Filing - Stock Titan
SPRY Should I Buy - Intellectia AI
From Clinical To Market: Managing Pharma's Most Challenging Transition - Life Science Leader
How The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future Valuation - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock? - MSN
(SPRY) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies - The Manila Times
SPRY Technical Analysis | Trend, Signals & Chart Patterns | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Food Allergy Market Expected to Experience Accelerated Growth - openPR.com
[Form 3] ARS Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Food Allergy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Novartis, Roche, ARS Pharma, ALK Abelló, Alfresa Pharma, Stallergenes Greer, DBV Techno - Barchart.com
ARS Pharmaceuticals Hits Day High with 10.59% Surge in Stock Price - Markets Mojo
Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential - Investing.com India
ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald - Moomoo
Liquidity Mapping Around (SPRY) Price Events - Stock Traders Daily
Creek Drive Management Group LLC's ARS Pharmaceuticals Inc(SPRY) Holding History - GuruFocus
Number of shareholders of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks - TipRanks
ARS Pharmaceuticals: Still A Buy As Neffy Access Improves (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals gears up for Q1 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
ARS Pharma (SPRY) Q1 2026 Earnings Transcript - AOL.com
Why (SPRY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ARS Pharmaceuticals, Inc. (SPRY) reports Q1 loss, beats revenue estimates - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
ARS Pharmaceuticals Q1 2026 Results: neffy® Drives $22.7M Revenue, U.S. and Global Expansion Updates - Minichart
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program - MSN
Transcript : ARS Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
ARS Pharma (SPRY) Q4 2025 Earnings Transcript - The Globe and Mail
ARS Pharmaceuticals 2026 Q1 10-Q: Financial Results, neffy™ Commercialization, and Key Risk Factors - Minichart
Rubric Capital (SPRY) reports 8.06% stake; 8,000,000 shares disclosed - Stock Titan
EX-99.1 - SEC.gov
ARS Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
SPRY: Q1 revenue hit $22.7M as neffy adoption surged, with expanded access set to drive further growth - TradingView
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ars Pharmaceuticals Inc-Aktie (SPRY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer |
Jun 12 '26 |
Sale |
10.00 |
25,000 |
250,000 |
12,176 |
| Fitzpatrick Alexander A | Chief Legal Officer |
Jun 12 '26 |
Sale |
10.00 |
3,355 |
33,550 |
90,910 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):